
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Bilirubin Pathways And Pitfalls: From Processing To Pathology</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Bilirubin Pathways And Pitfalls: From Processing To Pathology</strong></summary>
            <div>
                <ul><li>Journal: AASLD Liver Fellow Network (LFN)</li><li>Publication Date: April 14, 2025</li><li>Topic: Core Series, Back to Basics</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of bilirubin is primarily derived from the catabolism of hemoglobin released from senescent red blood cells?</li><li>2. At what serum bilirubin level do clinical features like jaundice typically become appreciable?</li><li>3. Which benign hereditary condition, affecting approximately 3-7% of individuals, results from a mild reduction in UGT1a1 enzyme activity?</li><li>4. What is the hallmark gross pathological feature of the liver in Dubin-Johnson syndrome?</li><li>5. Why is bilirubin considered an important component in liver disease scoring systems?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bilirubin Metabolism: Physiology &amp; Importance</strong></summary>
            <div>
                <ul><li>Bilirubin processing reflects liver function, specifically its ability to clear metabolic waste.</li><li>Understanding bilirubin metabolism is essential for recognizing jaundice and liver pathophysiology.</li></ul>
                
        <details>
            <summary><strong>Bilirubin Sources</strong></summary>
            <div>
                <ul><li>70% of bilirubin → catabolism of hemoglobin from senescent red blood cells.</li><li>10% → ineffective erythropoiesis.</li><li>20% → breakdown of heme-containing proteins in hepatocytes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Unconjugated Bilirubin (UCB)</strong></summary>
            <div>
                <ul><li>Hydrophobic; must bind albumin in plasma for transport to liver.</li><li>Albumin binding is crucial for hepatic uptake.</li></ul>
                
        <details>
            <summary><strong>Albumin Role</strong></summary>
            <div>
                <ul><li>Low albumin levels → impair bilirubin clearance.</li><li>↓ binding capacity &amp; affinity for bilirubin → ↓ hepatic uptake.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conjugated Bilirubin (CB)</strong></summary>
            <div>
                <ul><li>Hydrophilic; enables biliary excretion w/o transport.</li><li>Excreted as waste products: stercobilin and urobilin.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hyperbilirubinemia: Impaired Processing</strong></summary>
            <div>
                <ul><li>Hyperbilirubinemia occurs w/ bilirubin accumulation.</li><li>Normal bilirubin level: &lt;1 mg/dL.</li><li>Clinical features appreciated when bilirubin levels &gt;3 mg/dL.</li></ul>
                
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>Jaundice: yellow discoloration of skin, sclera (scleral icterus), mucous membranes.</li><li>Dark urine: due to ↑ urinary excretion of conjugated bilirubin.</li><li>Pale (acholic) stools: due to ↓ bilirubin reaching intestines.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Types of Hyperbilirubinemia</strong></summary>
            <div>
                <ul><li>Differentiating between unconjugated and conjugated hyperbilirubinemia is key for diagnosis.</li><li>Alterations in bilirubin metabolism lead to various conditions.</li></ul>
                
        <details>
            <summary><strong>Unconjugated Hyperbilirubinemia (UCB)</strong></summary>
            <div>
                <ul><li>Occurs w/ impaired hepatic bilirubin uptake AND/OR ↑ heme turnover/hemolysis.</li><li>Key enzyme for glucuronidation is UGT1a1.</li></ul>
                
        <details>
            <summary><strong>Key Enzyme: UGT1a1</strong></summary>
            <div>
                <ul><li>Uridine diphosphate-glucuronosyltransferase 1a1 (UGT1a1) catalyzes glucuronidation.</li><li>Glucuronidation: converts unconjugated bilirubin to conjugated bilirubin.</li><li>Gene mutations → reduced enzyme activity → UCB.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Conditions</strong></summary>
            <div>
                <ul><li>Conditions caused by UGT1a1 gene mutations.</li></ul>
                
        <details>
            <summary><strong>Gilbert Syndrome</strong></summary>
            <div>
                <ul><li>Benign hereditary condition; mild ↓ UGT1a1 enzyme activity (~30% gene activity).</li><li>Prevalence: ≈3-7% of individuals.</li><li>Patients generally asymptomatic outside of jaundice.</li><li>Jaundice commonly occurs w/ stressors: dehydration, fasting, illness, menstruation.</li><li>Serum bilirubin level: modest, usually &lt;3 mg/dL.</li><li>Diagnosis: inferred from mild ↑ UCB, clinical picture, rule out hemolysis/liver disease.</li><li>Genetic testing rarely pursued; condition is benign, self-resolves w/ stressor resolution.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Crigler-Najjar Syndrome</strong></summary>
            <div>
                <ul><li>Inherited autosomal recessive condition.</li><li>Results from moderate (Type 2) or complete (Type 1) absence of UGT1a1 enzyme.</li><li>UCB present @ birth; persistent elevation in serum bilirubin.</li></ul>
                
        <details>
            <summary><strong>Type 1</strong></summary>
            <div>
                <ul><li>Complete absence of UGT1a1 enzyme.</li><li>Serum bilirubin range: 20-45 mg/dL.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Type 2</strong></summary>
            <div>
                <ul><li>Moderate reduction of UGT1a1 enzyme.</li><li>Serum bilirubin range: 5-25 mg/dL.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hemolysis</strong></summary>
            <div>
                <ul><li>↑ red blood cell turnover → rate of heme metabolism &amp; UCB production exceeds conversion rate.</li><li>Serum bilirubin levels rarely exceed 4-5 mg/dL in hemolysis disorders.</li><li>Patients tend to have normal liver function.</li></ul>
                
        <details>
            <summary><strong>Evaluation</strong></summary>
            <div>
                <ul><li>Blood tests to evaluate for hemolysis: LDH, haptoglobin, reticulocyte count, peripheral blood smear.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Causes</strong></summary>
            <div>
                <ul><li>Blood transfusion reactions (intra- &amp; extra-vascular hemolysis).</li><li>Trauma w/ severe injury: induces intravascular hemolysis, ↑ lysis of native &amp; transfused RBCs.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conjugated Hyperbilirubinemia (CB)</strong></summary>
            <div>
                <ul><li>Occurs w/ intrahepatic AND/OR extrahepatic cholestasis.</li><li>Intrahepatic cholestasis: conditions impairing hepatic excretion of CB into bile canaliculi.</li><li>Extrahepatic cholestasis: obstruction of bile ducts outside liver, preventing CB from reaching intestines.</li></ul>
                
        <details>
            <summary><strong>Cholestasis Impact</strong></summary>
            <div>
                <ul><li>Primary impact: bile acid transport.</li><li>Also results in CB due to impaired hepatobiliary transport &amp; transport protein function.</li><li>Metabolism of bilirubin is mostly independent from bile acid metabolism.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Conditions</strong></summary>
            <div>
                <ul><li>Rare, benign autosomal inherited disorders.</li></ul>
                
        <details>
            <summary><strong>Dubin-Johnson Syndrome</strong></summary>
            <div>
                <ul><li>Impaired hepatic excretion of bilirubin due to gene mutations.</li><li>Results in impaired function of multidrug resistance-associated protein 2 (MRP2) transporter.</li><li>Hallmark feature: liver appears black due to impaired metabolite excretion.</li><li>Patients generally asymptomatic outside of mild jaundice; normal LFTs, no hemolysis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rotor Syndrome</strong></summary>
            <div>
                <ul><li>Impaired hepatic uptake of bilirubin due to gene mutations.</li><li>Results in impaired function of organic anion-transporting polypeptides (OATPs).</li><li>Some CB enters hepatocytes from bloodstream via OATPs re-uptake.</li><li>Patients generally asymptomatic outside of mild jaundice; normal LFTs, no hemolysis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Bilirubin as Liver Dysfunction Indicator</strong></summary>
            <div>
                <ul><li>Elevated bilirubin can be an early warning signal of hepatic dysfunction.</li><li>Important clinical clue to a patient’s synthetic dysfunction, informing decision-making in advanced liver disease.</li></ul>
                
        <details>
            <summary><strong>Scoring Systems &amp; Models</strong></summary>
            <div>
                <ul><li>Several systems leverage bilirubin&#x27;s role in liver&#x27;s waste metabolism.</li><li>Examples found on mdcalc.com.</li><li>Bilirubin is a key component, alongside abnormal coagulation factors, for assessing synthetic dysfunction.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Take-Home Points</strong></summary>
            <div>
                <ul><li>Bilirubin metabolism: series of steps following hemoglobin breakdown → excretion of conjugated bilirubin as stercobilin &amp; urobilin.</li><li>Impaired bilirubin metabolism: occurs w/ intrahepatic &amp; extrahepatic cholestasis → unconjugated AND/OR conjugated hyperbilirubinemia.</li><li>Clinical features of hyperbilirubinemia: scleral icterus, jaundice, pale stools, dark urine.</li><li>Elevated bilirubin levels: reflection of liver disease &amp; synthetic dysfunction; key component of commonly used liver disease scoring systems.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
